NEW YORK, NY--(Marketwired - November 15, 2016) - Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), a life sciences technology Company, announced that it will form a new wholly owned subsidiary focused on the development, marketing and distribution of products that target muscle tension. Muscle tension is a condition in which muscles of the body remain semi-contracted for an extended period. Muscle tension is typically caused by the physiological effects of stress and can lead to episodes of neck, shoulder and back pain as well as migraines.
The Company plans to complete the formation of this new wholly owned subsidiary within the next 30 days and will keep shareholders informed of progress. The subsidiary will be called ColluMauxil Therapeutics LLC ("ColluMauxil"), which is based on the Latin terms for neck relief -- "collum" and "auxilium." The Company has already contracted the services of New Jersey based PrintComm to establish the graphics and logo associated with ColluMauxil.
Tauriga plans to develop, market, distribute and potentially license a broad array of products and technologies that may help individuals who are affected by muscle tension. The Company has already identified potential products and technologies of interest and is actively working towards the goal of creating an innovative product line to launch the business activities of ColluMauxil. The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments.
Additionally, the Company plans on developing a product that specifically targets muscle tension in the neck, shoulder, and upper back. The Company envisions that this product will incorporate a roll-on delivery system ("Roll-On Product") which is easier to apply to a specific area on the body. The Company also plans to develop a Roll-On Product that incorporates CBD Oil ("Cannabis Oil"), which is a legal alternative to THC oil, and it is available for sale in all states as well as around the world. Cannabis Oil is widely believed to provide relief to individuals who suffer from muscle tension, tenderness, and pain. Both contemplated Roll-On Products will be branded under the ColluMauxil name.
However, until these contemplated products are completed and distributed to the retail market, there can be no guaranty that any revenue will ever be generated. The Company believes it can raise the necessary funds to develop and begin distribution of its first muscles tension product for approximately $200,000, which it hopes to obtain through equity financing ("private placement"). The Company is confident that it will regain fully reporting status during the current quarter, which enables it to rely on Rule 144 for financing activities. The Company believes none of the contemplated products to be developed under the ColluMauxil brand will require approval from the Food and Drug Administration.
When the body is stressed, muscles tense up. Muscle tension is almost a reflex reaction to stress -- the body's way of guarding against injury and pain. With sudden onset stress, the muscles tense up all at once, and then release their tension when the stress passes. Chronic stress causes the muscles in the body to be in a more or less constant state of guardedness. When muscles are taut and tense for long periods of time, this may trigger other reactions of the body and even promote stress-related disorders. For example, both tension-type headache and migraine headache are associated with chronic muscle tension in the area of the shoulders, neck and head. Millions of Americans suffer from chronic painful conditions secondary to musculoskeletal disorders.
Tauriga's Chief Executive Officer, Seth M. Shaw, expressed, "The Company and its management have worked hard to establish a business model that leverages the Company's strengths and valuable relationships. The formation of ColluMauxil enables the Company to focus on launching a multi-faceted business model that has the potential to both restore and create shareholder value. As someone who has personally suffered from both chronic muscle tension and tension migraines, I fully understand how painful and debilitating this type of condition can be. The Company will focus on introducing and marketing innovative products and technologies with the equally important goals of generating profitable revenue and helping individuals in the process."
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on Tauriga's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which Tauriga has little or no control. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by Tauriga with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.